NovoCure Limited 038.F Stock
NovoCure Limited Price Chart
NovoCure Limited 038.F Financial and Trading Overview
| NovoCure Limited stock price | 13.1 EUR |
| Previous Close | 40.11 EUR |
| Open | 40 EUR |
| Bid | 40 EUR x 50000 |
| Ask | 43.37 EUR x 40000 |
| Day's Range | 40 - 40 EUR |
| 52 Week Range | 39.27 - 144.6 EUR |
| Volume | 100 EUR |
| Avg. Volume | 30 EUR |
| Market Cap | 4.31B EUR |
| Beta (5Y Monthly) | 0.795422 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.82 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 177.14 EUR |
038.F Valuation Measures
| Enterprise Value | 3.89B EUR |
| Trailing P/E | N/A |
| Forward P/E | -2000 |
| PEG Ratio (5 yr expected) | -7.8 |
| Price/Sales (ttm) | 8.239935 |
| Price/Book (mrq) | 9.82801 |
| Enterprise Value/Revenue | 7.442 |
| Enterprise Value/EBITDA | -28.039 |
Trading Information
NovoCure Limited Stock Price History
| Beta (5Y Monthly) | 0.795422 |
| 52-Week Change | -22.90% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 144.6 EUR |
| 52 Week Low | 39.27 EUR |
| 50-Day Moving Average | 59.72 EUR |
| 200-Day Moving Average | 71.34 EUR |
038.F Share Statistics
| Avg. Volume (3 month) | 30 EUR |
| Avg. Daily Volume (10-Days) | 103 EUR |
| Shares Outstanding | 106.21M |
| Float | 95.02M |
| Short Ratio | N/A |
| % Held by Insiders | 1.18% |
| % Held by Institutions | 81.01% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -26.97% |
| Operating Margin (ttm) | -28.39% |
| Gross Margin | 77.77% |
| EBITDA Margin | -26.54% |
Management Effectiveness
| Return on Assets (ttm) | -7.97% |
| Return on Equity (ttm) | -32.47% |
Income Statement
| Revenue (ttm) | 522.48M EUR |
| Revenue Per Share (ttm) | 4.97 EUR |
| Quarterly Revenue Growth (yoy) | -11.20% |
| Gross Profit (ttm) | 423.58M EUR |
| EBITDA | -138675008 EUR |
| Net Income Avi to Common (ttm) | -140948000 EUR |
| Diluted EPS (ttm) | -1.32 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 958.04M EUR |
| Total Cash Per Share (mrq) | 9.02 EUR |
| Total Debt (mrq) | 586.3M EUR |
| Total Debt/Equity (mrq) | 135.67 EUR |
| Current Ratio (mrq) | 7.32 |
| Book Value Per Share (mrq) | 4.07 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 17.75M EUR |
| Levered Free Cash Flow (ttm) | 164.19M EUR |
Profile of NovoCure Limited
| Country | Germany |
| State | N/A |
| City | Saint Helier |
| Address | No. 4 The Forum |
| ZIP | JE2 4UF |
| Phone | 44 15 3475 6700 |
| Website | https://www.novocure.com |
| Industry | Medical Devices |
| Sector(s) | Healthcare |
| Full Time Employees | 1320 |
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. The company was incorporated in 2000 and is headquartered in Saint Helier, Jersey.
Q&A For NovoCure Limited Stock
What is a current 038.F stock price?
NovoCure Limited 038.F stock price today per share is 13.1 EUR.
How to purchase NovoCure Limited stock?
You can buy 038.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for NovoCure Limited?
The stock symbol or ticker of NovoCure Limited is 038.F.
Which industry does the NovoCure Limited company belong to?
The NovoCure Limited industry is Medical Devices.
How many shares does NovoCure Limited have in circulation?
The max supply of NovoCure Limited shares is 107.09M.
What is NovoCure Limited Price to Earnings Ratio (PE Ratio)?
NovoCure Limited PE Ratio is now.
What was NovoCure Limited earnings per share over the trailing 12 months (TTM)?
NovoCure Limited EPS is -1.82 EUR over the trailing 12 months.
Which sector does the NovoCure Limited company belong to?
The NovoCure Limited sector is Healthcare.